Download MendeleyDiscovery of triazole aminopyrazines as a highly potent and selective series of PI3K delta inhibitors.
Terstiege, I., Perry, M., Petersen, J., Tyrchan, C., Svensson, T., Lindmark, H., Oster, L.(2017) Bioorg Med Chem Lett 27: 679-687
- PubMed: 28017532
- DOI: https://doi.org/10.1016/j.bmcl.2016.11.004
- Primary Citation of Related Structures:
5T23, 5T27, 5T28, 5T2B, 5T2D, 5T2G, 5T2I, 5T2L, 5T2M - PubMed Abstract:
A novel class of potent PI3Kδ inhibitors with >1000-fold selectivity against other class I PI3K isoforms is described. Optimization of the substituents on a triazole aminopyrazine scaffold, emerging from an in-house PI3Kα program, turned moderately selective PI3Kδ compounds into highly potent and selective PI3Kδ inhibitors. These efforts resulted in a series of aminopyrazines with PI3Kδ IC 50 ⩽1nM in the enzyme assay, some of the most selective PI3Kδ inhibitors published to date, with a cell potency in a JeKo-cell assay of 20-120nM.
Organizational Affiliation:
Respiratory, Inflammation & Autoimmunity, Innovative Medicines and Early Development Biotech Unit, AstraZeneca, Pepparedsleden 1, Mölndal, 43183, Sweden. Electronic address: Ina.Terstiege@astrazeneca.com.
